Aliskiren

證據等級: L5

預測適應症: 7 個

Using the TxGNN evidence-pack fields directly (no fabrication) to produce the report below. Since original_indications and licenses are empty and original_moa is [Data Gap], I've flagged those explicitly rather than inventing data, and I focus the templated sections on predicted_indications[0] (the highest-scoring candidate) as the format specifies.

Aliskiren: From Hypertension to Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia

Note: the evidence pack contains no original_indications text and no Norway license records for aliskiren, so the "original indication" below is stated from the drug's known pharmacological class (direct renin inhibitor, indicated for essential hypertension), not from pack data.

One-Sentence Summary

Aliskiren is a direct renin inhibitor originally developed for essential hypertension. The TxGNN model predicts it may be effective for pulmonary hypertension owing to lung disease and/or hypoxia, but this direction is currently supported only by the model's score — 0 clinical trials and none of the 20 retrieved publications actually study aliskiren, RAAS inhibition, or pulmonary hypertension. This is an algorithm-only signal, not a drug-specific finding.

Quick Overview

Item	Content
Original Indication	Essential hypertension (from known drug class; not present in evidence pack — no `original_indications` or Norway license text supplied)
Predicted New Indication	Pulmonary hypertension owing to lung disease and/or hypoxia
TxGNN Prediction Score	99.98%
Evidence Level	L5 (model prediction only)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (marked as a High-severity data gap, DG002). Based on known pharmacology, aliskiren is a direct renin inhibitor (DRI) that blocks the rate-limiting step of the renin-angiotensin-aldosterone system (RAAS), and its efficacy in essential hypertension is well established.

The theoretical link to pulmonary hypertension is that chronic hypoxia can locally activate RAAS and promote pulmonary vascular remodeling, which in principle could make renin inhibition a plausible intervention point. This is a biologically coherent hypothesis, not a proven one.

Critically, none of the 20 literature records returned for this pairing mention aliskiren, RAAS inhibitors, or pulmonary hypertension treatment — they are general hypoxia-biology and neurodegeneration literature (e.g., high-altitude physiology, cognitive impairment under hypoxia, tumor hypoxia signaling). No clinical trials were identified either. The TxGNN score therefore reflects a pure graph-based association, with no drug-specific mechanistic or clinical corroboration in the current evidence pack.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

All 20 retrieved publications concern hypoxia biology in general and do not specifically address aliskiren, RAAS inhibition, or pulmonary hypertension. They are listed below for transparency, prioritized by review-type classification (no RCTs were returned):

PMID	Year	Type	Journal	Key Findings
33862277	2021	Review	Ageing Research Reviews	Hypoxia's dual role in neurodegeneration vs. potential neuroprotection at altitude/in disease; no drug-specific content
34618295	2022	Review	Metabolic Brain Disease	Cognitive impairment mechanisms under acute vs. chronic hypoxia
21328446	2011	Review	Journal of Cellular Biochemistry	General hypoxia-mediated biological control (metabolism, angiogenesis, disease)
11172576	2000	Review	Respiratory Care Clinics of North America	Mechanisms of hypoxemia (V/Q mismatch, shunt, hypoventilation) — general respiratory physiology
34535359	2021	Review	Clinical Oncology	Therapeutic modification of tumor hypoxia (radiotherapy resistance context)
31961750	2020	Review	Annual Review of Immunology	HIF pathway role in innate immunity/inflammation
28219680	2017	Review	Experimental Cell Research	Transcriptional repression mechanisms under hypoxia (HIF regulation)
40347693	2025	Review	Redox Biology	Hypoxia's role in multiple sclerosis pathology
27146279	2017	Review	Cephalalgia	Hypoxic mechanisms in primary headache disorders
36100192	2022	Review	Journal of Controlled Release	Tumor hypoxia-associated nanomedicine strategies

10 of 20 records shown (prioritized by Review classification); the remaining 10 are lower-tier/uncategorized ("pending") records on unrelated hypoxia topics (e.g., cancer HIF signaling, cerebral anoxia case reports) and add no additional relevance.

Norway Market Information

Aliskiren currently has no marketing authorization in Norway (status: Not Marketed; 0 licenses on file). No product, dosage form, or approved-indication data is available from Norwegian regulatory records.

Safety Considerations

Please refer to the package insert for safety information. Note that the evidence pack flags TFDA/label-equivalent warnings and contraindications as a Blocking data gap (DG001) — this specifically prevents the candidate from entering the S1 safety pre-assessment stage, independent of the efficacy evidence discussed above.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but the supporting evidence is L5 (model prediction only) — there are no clinical trials and no literature that actually studies aliskiren, RAAS inhibition, or pulmonary hypertension. Combined with a Blocking gap on safety/label data and no market presence in Norway, there is no basis to advance this indication pairing beyond hypothesis stage.

To proceed, the following is needed:

TFDA-equivalent package insert data (warnings, contraindications) to clear the Blocking gap (DG001) and allow entry into S1 safety pre-assessment
Detailed mechanism-of-action documentation (DG002) to substantiate the RAAS–hypoxia–pulmonary vascular remodeling rationale
Aliskiren- or RAAS-inhibitor-specific preclinical or clinical studies in pulmonary hypertension (none currently exist in the retrieved literature)
For context: the evidence pack also lists 6 other predicted indications for aliskiren with substantially different evidence profiles — notably "cerebrovascular disorder" (L2, includes ALTITUDE-trial post-hoc data), though that evidence shows an increased risk of stroke/hypotension with aliskiren + ACEI/ARB combination therapy rather than benefit, and should be reviewed as a safety signal, not a repurposing opportunity, before any further action on this drug
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.